PRIMARY TRACK: Evidence generation and synthesis SECONDARY TRACK: Cost-effectiveness research BACKGROUND (INTRODUCTION): An economic model was developed for the LUTS Guideline to compare the cost-effectiveness of a drug combination therapy with a single drug in men with LUTS. In order to estimate quality-adjusted life years (QALYs), we linked patient-reported outcomes into quality-of-life (QoL) measures using the minimal important difference (MID) as identified with GRADE. PURPOSE: To describe how using GRADE helped in the construction of an economic model.
LEARNING OBJECTIVES (TRAINING GOALS):
1. Use the minimal important difference in the construction of an economic model. 2. Understand the importance of a close collaboration between reviewers and health economists. METHODS: The MID for International Prostate Symptom Score (IPSS, range 0-35) was determined for the purpose of imprecision grading in GRADE and for determining what was a clinically important result. We linked this variable to the effectiveness in the model and we analyzed how results changed when the MID was varied. RESULTS: The Guideline Development Group considered the MID for IPSS to be 3 points; in the model, the proportion of patients with at least this improvement in each arm was estimated and constituted the remission group. QoL values associated with remission were used for this group while QoL values associated with LUTS were used for the remaining group of patients. The combination strategy was not costeffective when an MID of 3 points was used. This strategy was still not cost-effective for any plausible value of MID. DISCUSSION (CONCLUSION): Estimating the MID could make a difference in the results of cost-effectiveness analyses for outcomes that have a big impact on QoL. Collaboration between clinical reviewers, health economists, and
